XML 95 R72.htm IDEA: XBRL DOCUMENT v3.6.0.2
Co-Development Agreements (Details)
$ in Thousands
3 Months Ended 12 Months Ended
Nov. 01, 2016
USD ($)
item
Sep. 21, 2016
USD ($)
Oct. 31, 2015
USD ($)
Feb. 03, 2015
USD ($)
item
Dec. 31, 2016
USD ($)
item
Sep. 30, 2016
USD ($)
Jun. 30, 2016
USD ($)
Mar. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Dec. 31, 2016
USD ($)
item
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Co-Development Agreements                              
Proceeds from private investment in public equity                         $ 39,723    
Revenues         $ 910 $ 1,084 $ 990 $ 1,096 $ 1,011 $ 1,049 $ 564 $ 189 4,080 $ 2,813 $ 119
Investor | Stock sale agreement | Canon U.S. Life Sciences Inc.                              
Co-Development Agreements                              
Proceeds from private investment in public equity   $ 39,700                          
Ownership percentage (as a percent)   19.90%                          
Co Development Partnership Agreement | Canon U.S. Life Sciences Inc.                              
Co-Development Agreements                              
Upfront payment       $ 2,000                      
Additional consideration receivable upon achievement of certain development and regulatory milestones       6,500                      
Aggregate consideration receivable       $ 8,500                      
Proceeds received for achievement of milestone     $ 1,500                        
Consideration eligible to receive upon achievement of specified technical requirement related to the achievement of the milestone         $ 5,000               $ 5,000    
Number of milestone payments | item         2               2    
Additional consideration receivable upon achievement of development and regulatory milestones, payment one         $ 2,000               $ 2,000    
Additional consideration receivable upon achievement of development and regulatory milestones, payment two         $ 3,000               3,000    
Number of units | item       1                      
Revenues                         $ 1,800 $ 1,400  
Co-Development, Collaboration and Co-Marketing Agreement | Allergan Sales, LLC                              
Co-Development Agreements                              
Upfront payment $ 2,000                            
Number of units | item 2                            
Number of additional bacteria species added to existing product candidate | item 1                            
Period entity expects to record revenue                         2 years    
Maximum | Co-Development, Collaboration and Co-Marketing Agreement | Allergan Sales, LLC                              
Co-Development Agreements                              
Additional consideration receivable upon achievement of certain development and regulatory milestones $ 4,000